Pre-operative gonadotrophin-releasing hormone agonist treatment in surgery for uterine leiomyomata

A. Golan*, I. Bukovsky, M. Pansky, D. Schneider, Z. Weinraub, E. Caspi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


To determine whether pre-operative treatment with gonadotrophin-releasing hormone (GnRH) analogue may have a beneficial effect on surgery outcome, 53 patients with symptomatic fibroid uteri awaiting myomectomy or transabdominal hysterectomy (TAH), were randomly divided into a study group (n = 29) and a control group (n = 24). The study group of patients were treated by an i.m. injection of D-Trp6 LHRH microcapsules at 2 months and 1 month prior to surgery. The control group had no pre-operative treatment. Haemoglobin concentration and oestradiol, follicle-stimulating hormone and luteinizing hormone concentrations were measured at 2 months and 1 month prior to surgery, and at surgery. The duration of surgery was shorter in the study group (49 versus 70 min in the hysterectomy group) and intraoperative blood loss was less (208 versus 309 ml in the hysterectomies and 320 versus 476 ml in the myomectomies). Pre-operative treatment with GnRH-agonists which induces shrinkage of the uterus and fibroids is therefore efficient in shortening the duration of surgery, and diminishing the intraoperative blood loss in surgery for fibroid uteri. Such preoperative treatment is therefore a useful addition to surgery in cases with symptomatic fibroid uteri.

Original languageEnglish
Pages (from-to)450-452
Number of pages3
JournalHuman Reproduction
Issue number3
StatePublished - Mar 1993
Externally publishedYes


  • GnRH agonist
  • Leiomyomata


Dive into the research topics of 'Pre-operative gonadotrophin-releasing hormone agonist treatment in surgery for uterine leiomyomata'. Together they form a unique fingerprint.

Cite this